Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS

BackgroundThe advent of tisagenlecleucel has been a major advance in the pharmacological treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and adolescents. However, further research is required to better define its safety profile.ObjectivesTo determine the cardiovascul...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ganggang Wang, Lin Su, Yanjun Liu, Xiaohan Yang, Yi Li, Qi Mei, Wen Gao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	tisagenlecleucel Adverse Event Reporting System data mining cardiovascular adverse event child
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1499143/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients
by: Bo Dai, et al.
Published: (2025-01-01)

Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
by: Ke Wang, et al.
Published: (2025-01-01)

Predictive risk factors for adverse events during tooth extraction among elderly patients with cardiovascular diseases
by: Shaojun Ma, et al.
Published: (2025-12-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01)

Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade
by: Nicholas H. Adamstein, MD, et al.
Published: (2025-03-01)

Construction and Comparison of Machine Learning-Based Risk Prediction Models for Major Adverse Cardiovascular Events in Perimenopausal Women
by: Chen A, et al.
Published: (2025-01-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials
by: Muhammed Favas Karimbanathottathil, et al.
Published: (2024-12-01)

Triglyceride‐glucose index trajectories predict adverse cardiovascular outcomes in elderly heart failure patients with Diabetes: A retrospective cohort study
by: Hong Liu, et al.
Published: (2024-12-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Visit-to-visit lipid variability on long-term major adverse cardiovascular events: a prospective multicentre cohort from the CORE-Thailand registry
by: Chutithep Teekaput, et al.
Published: (2025-01-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
by: Wenwen Zhang, et al.
Published: (2025-01-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease
by: Qianhui Li, et al.
Published: (2025-01-01)

Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score
by: Yi Hui To, et al.
Published: (2023-02-01)

Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review
by: Man Sun, et al.
Published: (2025-01-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

Surgical treatment of anomalous aortic origin of the coronary artery in paediatric patients: a Chinese single-center experience
by: Kai Luo, et al.
Published: (2025-01-01)

Antithrombotic therapy in adults with ectatic coronary artery disease: a systematic review and network meta-analysis
by: Alireza Azarboo, et al.
Published: (2025-01-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Association between cardiopulmonary bypass duration and early major adverse cardiovascular events after surgical repair of supravalvular aortic stenosis
by: Simeng Zhang, et al.
Published: (2025-01-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Association between triglyceride glucose index and adverse cardiovascular prognosis in patients with atrial fibrillation without diabetes: a retrospective cohort study
by: Aobo Gong, et al.
Published: (2025-01-01)

Major adverse cardiovascular events among Black and White Veterans receiving androgen deprivation therapy for prostate cancer: a retrospective cohort study
by: Alexander R. Lucas, et al.
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)